Defending the right of Russians to health

According to the Russian pharma trade body the ARPM, the 2nd Annual “Right to Health” Congress was held in Moscow, aimed to highlight the prospects of the domestic healthcare industry, which have become more acute in modern geopolitical conditions, in a wide format.

The growth in the cost of drug manufacturing has a particularly acute effect on the assortment availability of pharmaceutical products included in the list of vital and essential drugs (VED). The Association of Russian Pharmaceutical Manufacturers has repeatedly appealed to the regulators, pointing out a significant increase in the cost of pharmaceutical substances, auxiliary raw materials and packaging materials for the industry, entailing a decrease in the profitability of the production of these drugs, and, as a result, the risks of their exit from the market, and putting forward a proposal on the need for a one-time indexation of maximum selling prices for medicines of the low price segment from the Vital and Essential Drugs List.

Once again, Viсtor Dmitriev, Chairman of the Public Council under the Federal Service for Surveillance in Healthcare (Roszdravnadzor), drew the attention of the audience to this problem.